LG Chem halts global Phase 3 trial for gout treatment drug to focus on anticancer new drug

LG Chem announced that it will voluntarily discontinue the global Phase 3 clinical trial of the gout treatment 'LC350189.'

According to industry sources on the 28th, LG Chem issued a notice the day before stating that the reason for halting the Phase 3 trial was due to "increased uncertainty in economic aspects such as recovering investment costs based on market research in the United States," adding that "it will focus on expanding its oncology drug pipeline with high growth potential."

Previously, LG Chem had received approval for the LC350189 clinical trial from regulatory agencies in 21 countries, including South Korea, the United States, and Europe. The treatment demonstrated superiority over placebo in last year's clinical trials.

This content was produced with the assistance of AI translation services.